Chemotherapy Resistance in Metastatic Breast Cancer: Evolving Role of Ixabepilone

New research sheds light on the need for new agents to combat chemotherapy resistance in metastatic breast cancer. According to a recent study published in the journal Breast Cancer Research, approximately 30% of women diagnosed with early-stage breast cancer progress to metastatic breast cancer, a condition with limited therapeutic options. Current chemotherapy recommendations, such as anthracycline-based regimens and taxanes, exhibit response rates of 30 to 70% but offer short-term benefits, with a median time to progression of 6 to 10 months. Patients with resistance or progression may be administered alternative treatments, including ixabepilone, with modest response rates of 20 to 30%.

Key Takeaways:

• Approximately 30% of women diagnosed with early-stage breast cancer progress to metastatic breast cancer, where therapeutic options are limited.
• Current chemotherapy recommendations, such as anthracycline-based regimens and taxanes, exhibit response rates of 30 to 70% but offer short-term benefits with a median time to progression of 6 to 10 months.
• Patients with resistance or progression may be administered alternative treatments, including ixabepilone, with modest response rates of 20 to 30%.
• The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting.
• Ixabepilone has demonstrated efficacy in taxane-resistant metastatic breast cancer, with response rates comparable to other alternative treatments.

Statistics:

• Approximately 30% of women diagnosed with early-stage breast cancer progress to metastatic breast cancer.
• Current chemotherapy recommendations exhibit response rates of 30 to 70%.
• Median time to progression for current chemotherapy recommendations is 6 to 10 months.
• Response rates for ixabepilone in taxane-resistant metastatic breast cancer range from 20 to 30%.

Sources:

• Rivera, E., et al. (2010). Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Research, 12 Suppl 2, S2.
• Gene Therapy Weekly editors, prepared by (2010). Chemotherapy resistance in metastatic breast cancer: evolving role of ixabepilone. Gene Therapy Weekly via NewsRx.com.